Takeda Pharms Usa Company Profile
What is the competitive landscape for TAKEDA PHARMS USA
TAKEDA PHARMS USA has forty approved drugs.
There are one hundred US patents protecting TAKEDA PHARMS USA drugs.
Summary for Takeda Pharms Usa
| US Patents: | 100 |
| Tradenames: | 43 |
| Ingredients: | 33 |
| NDAs: | 40 |
Drugs and US Patents for Takeda Pharms Usa
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | EOHILIA | budesonide | SUSPENSION;ORAL | 213976-001 | Feb 9, 2024 | RX | Yes | Yes | 11,357,859 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-002 | Nov 20, 2015 | RX | Yes | No | 7,442,830 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-001 | Nov 20, 2015 | RX | Yes | No | 7,687,662 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Takeda Pharms Usa | OSENI | alogliptin benzoate; pioglitazone hydrochloride | TABLET;ORAL | 022426-006 | Jan 25, 2013 | DISCN | Yes | No | 8,637,079 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Takeda Pharms Usa | COLCRYS | colchicine | TABLET;ORAL | 022352-001 | Jul 29, 2009 | DISCN | Yes | No | 8,415,396 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Takeda Pharms Usa | EOHILIA | budesonide | SUSPENSION;ORAL | 213976-001 | Feb 9, 2024 | RX | Yes | Yes | 11,564,934 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Takeda Pharms Usa
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-001 | Jan 30, 2009 | 9,238,029 | ⤷ Start Trial |
| Takeda Pharms Usa | NESINA | alogliptin benzoate | TABLET;ORAL | 022271-003 | Jan 25, 2013 | 8,288,539 | ⤷ Start Trial |
| Takeda Pharms Usa | OSENI | alogliptin benzoate; pioglitazone hydrochloride | TABLET;ORAL | 022426-002 | Jan 25, 2013 | 5,965,584 | ⤷ Start Trial |
| Takeda Pharms Usa | NESINA | alogliptin benzoate | TABLET;ORAL | 022271-003 | Jan 25, 2013 | 6,211,205 | ⤷ Start Trial |
| Takeda Pharms Usa | FOSRENOL | lanthanum carbonate | POWDER;ORAL | 204734-002 | Sep 24, 2014 | 5,968,976 | ⤷ Start Trial |
| Takeda Pharms Usa | OMONTYS | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-007 | Mar 27, 2012 | 7,919,118 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TAKEDA PHARMS USA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg | ➤ Subscribe | 2011-02-23 |
| ➤ Subscribe | Injection | 10 mg/mL | ➤ Subscribe | 2015-08-25 |
| ➤ Subscribe | Oral Powder | 750 mg and 1000 mg | ➤ Subscribe | 2015-11-25 |
| ➤ Subscribe | Extended-release Tablets | 15 mg/1000 mg and 30 mg/1000 mg | ➤ Subscribe | 2011-09-23 |
| ➤ Subscribe | Tablets | 15 mg/500 mg and 15 mg/850 mg | ➤ Subscribe | 2008-03-06 |
| ➤ Subscribe | Delayed-release Pellets/Capsul | 15 mg and 30 mg | ➤ Subscribe | 2005-12-05 |
| ➤ Subscribe | Tablets | 30 mg/2 mg and 30 mg/4 mg | ➤ Subscribe | 2009-12-22 |
| ➤ Subscribe | Capsule | 60 mg | ➤ Subscribe | 2010-08-25 |
| ➤ Subscribe | Tablets | 6.25 mg, 12.5 mg and 25 mg | ➤ Subscribe | 2017-01-25 |
| ➤ Subscribe | Extended-release Capsules | 100 mg and 200 mg | ➤ Subscribe | 2006-02-02 |
| ➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mgand 20 mg | ➤ Subscribe | 2017-10-02 |
| ➤ Subscribe | Extended-release Capsules | 12.5 mg and 25 mg | ➤ Subscribe | 2017-08-07 |
| ➤ Subscribe | For Injection | 3.5 mg/vial | ➤ Subscribe | 2008-11-20 |
| ➤ Subscribe | Chewable Tablet | 500 mg, 750 mg and 1000 mg | ➤ Subscribe | 2008-10-27 |
| ➤ Subscribe | Delayed-release Tablets | 1.2 g | ➤ Subscribe | 2009-12-16 |
| ➤ Subscribe | Extended-release Tablets | 1 mg, 2 mg, 3 mg and 4 mg | ➤ Subscribe | 2009-12-29 |
| ➤ Subscribe | Tablets | 0.6 mg | ➤ Subscribe | 2011-12-23 |
| ➤ Subscribe | Delayed-release Orally Disinte | 15 mg and 30 mg | ➤ Subscribe | 2006-12-27 |
| ➤ Subscribe | Tablets | 12.5 mg/500 mg and 12.5 mg/1000 mg | ➤ Subscribe | 2017-01-25 |
| ➤ Subscribe | Delayed-release Capsule | 30 mg | ➤ Subscribe | 2010-11-30 |
| ➤ Subscribe | Tablets | 8 mg | ➤ Subscribe | 2009-07-22 |
| ➤ Subscribe | Extended-release Capsules | 37.5 mg and50 mg | ➤ Subscribe | 2017-08-03 |
| ➤ Subscribe | Tablets | 40 mg and 80 mg | ➤ Subscribe | 2013-02-13 |
International Patents for Takeda Pharms Usa Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 118845797 | ⤷ Start Trial |
| New Zealand | 531556 | ⤷ Start Trial |
| European Patent Office | 3574914 | ⤷ Start Trial |
| Argentina | 054238 | ⤷ Start Trial |
| Peru | 20170268 | ⤷ Start Trial |
| Lithuania | 2328553 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Takeda Pharms Usa Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1436271 | C01436271/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: VORTIOXETINE; REGISTRATION NO/DATE: SWISSMEDIC 65937 09.06.2016 |
| 1586571 | C300640 | Netherlands | ⤷ Start Trial | PRODUCT NAME: ALOGLIPTINE IN ALLE VORMEN ZOALS BESCHERMD DOOR HET BASISOCTROOI; REGISTRATION NO/DATE: EU/1/13/844/001-007 20130923 |
| 2178888 | PA2017010 | Lithuania | ⤷ Start Trial | PRODUCT NAME: IKSAZOMIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS IR ESTERIAI, PAVYZDZIUI KAIP IKSAZOMIBO CITRATAS; REGISTRATION NO/DATE: EU/1/16/1094 20161121 |
| 2435024 | 132021000000095 | Italy | ⤷ Start Trial | PRODUCT NAME: UNA COMBINAZIONE DI FORMOTEROLO (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI), GLICOPIRROLATO (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI) E BUDESONIDE (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI)(TRIXEO AEROSPHERE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1498, 20201210 |
| 1644019 | SPC/GB13/052 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: LISDEXAMFETAMINE OPTIONALLY IN THE FORM OF A MESYLATE OR HYDROCHLORIDE SALT THEREOF; REGISTERED: UK PL08081/0050-2 20130201; UK PL08081/0062-4 20130201 |
| 1506211 | 42/2014 | Austria | ⤷ Start Trial | PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON UND METFORMIN UND EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON; REGISTRATION NO/DATE: EU/1/13/900 (MITTEILUNG) 20140121 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
